Resistance to Drugs and Cell Death in Cancer Stem Cells (CSCs)

Overview

Journal J Transl Sci

Publisher Open Access Text

Date 2022 Mar 25

PMID 35330670

Authors

Ahmad R Safa

Affiliations

Soon will be listed here.

Abstract

Human cancers emerge from cancer stem cells (CSCs), which are resistant to cancer chemotherapeutic agents, radiation, and cell death. Moreover, autophagy provides the cytoprotective effect which contributes to drug resistance in these cells. Furthermore, much evidence shows that CSCs cause tumor initiation, progression, metastasis, and cancer recurrence. Various signaling pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), maternal embryonic leucine zipper kinase (MELK), NOTCH1, and Wnt/β-catenin as well as the CSC markers maintain CSC properties. Several mechanisms including overexpression of ABC multidrug resistance transporters, a deficiency in mitochondrial-mediated apoptosis, upregulation of c-FLIP, overexpression of anti-apoptotic Bcl-2 family members and inhibitors of apoptosis proteins (IAPs), and PI3K/AKT signaling contribute to enhancing resistance to chemotherapeutic drugs and cell death induction in CSCs in various cancers. Studying such pathways may help provide detailed understanding of CSC mechanisms of resistance to chemotherapeutic agents and apoptosis and may lead to the development of effective therapeutics to eradicate CSCs.

Citing Articles

Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy.

Mengistu B, Tsegaw T, Demessie Y, Getnet K, Bitew A, Kinde M Cancer Cell Int. 2024; 24(1):406.

PMID: 39695669 PMC: 11657890. DOI: 10.1186/s12935-024-03558-0.

The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.

Masciale V, Banchelli F, Grisendi G, Samarelli A, Raineri G, Rossi T J Biol Chem. 2024; 300(12):107994.

PMID: 39547513 PMC: 11714729. DOI: 10.1016/j.jbc.2024.107994.

Medicinal plants as a potential resource for the discovery of novel structures towards cancer drug resistance treatment.

Nguyen M, Nguyen T, Le T, Le T, Chau N, Le T Heliyon. 2024; 10(20):e39229.

PMID: 39492898 PMC: 11530815. DOI: 10.1016/j.heliyon.2024.e39229.

Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.

Sarkar R, Biswas S, Ghosh R, Samanta P, Pakhira S, Mondal M J Nanobiotechnology. 2024; 22(1):285.

PMID: 38796426 PMC: 11127288. DOI: 10.1186/s12951-024-02518-0.

Downregulation of BUBR1 regulates the proliferation and cell cycle of breast cancer cells and increases the sensitivity of cells to cisplatin.

Lu Y, Wang R, He S, Zhang Q, Wei J, Hu J In Vitro Cell Dev Biol Anim. 2023; 59(10):778-789.

PMID: 38048028 DOI: 10.1007/s11626-023-00823-w.

References

Saygin C, Matei D, Majeti R, Reizes O, Lathia J . Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell Stem Cell. 2019; 24(1):25-40. DOI: 10.1016/j.stem.2018.11.017. View

Wong A, Bellot G, Hirpara J, Pervaiz S . Understanding the cancer stem cell phenotype: A step forward in the therapeutic management of cancer. Biochem Pharmacol. 2019; 162:79-88. DOI: 10.1016/j.bcp.2019.01.020. View

Perusina Lanfranca M, Thompson J, Bednar F, Halbrook C, Lyssiotis C, Levi B . Metabolism and epigenetics of pancreatic cancer stem cells. Semin Cancer Biol. 2018; 57:19-26. PMC: 6438777. DOI: 10.1016/j.semcancer.2018.09.008. View

Yuan Z, Mo J, Zhao G, Shu G, Fu H, Zhao W . Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells. Front Pharmacol. 2016; 7:423. PMC: 5103413. DOI: 10.3389/fphar.2016.00423. View

Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail A . Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest. 2011; 29(8):511-20. PMC: 3255792. DOI: 10.3109/07357907.2011.605412. View

Safa A . Roles of c-FLIP in Apoptosis, Necroptosis, and Autophagy. J Carcinog Mutagen. 2014; Suppl 6. PMC: 4219646. DOI: 10.4172/2157-2518.S6-003. View

Zhou J, Zhang H, Gu P, Bai J, Margolick J, Zhang Y . NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat. 2007; 111(3):419-27. PMC: 3320112. DOI: 10.1007/s10549-007-9798-y. View

Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B . The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019; 698:120-128. DOI: 10.1016/j.gene.2019.02.076. View

Zang F, Wei X, Leng X, Yu M, Sun B . C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer. Biochem Biophys Res Commun. 2014; 450(1):267-73. DOI: 10.1016/j.bbrc.2014.05.106. View

10.

Hata A, Engelman J, Faber A . The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov. 2015; 5(5):475-87. PMC: 4727530. DOI: 10.1158/2159-8290.CD-15-0011. View

11.

Knight T, Luedtke D, Edwards H, Taub J, Ge Y . A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol. 2019; 162:250-261. DOI: 10.1016/j.bcp.2019.01.015. View

12.

Yoon M, Kang Y, Kim I, Kim E, Lee J, Lim J . Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis. 2013; 34(8):1918-28. DOI: 10.1093/carcin/bgt137. View

13.

Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk D, Guan D . Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 2015; 75(6):924-9. PMC: 4359955. DOI: 10.1158/0008-5472.CAN-14-3225. View

14.

Toledo-Guzman M, Bigoni-Ordonez G, Ibanez Hernandez M, Ortiz-Sanchez E . Cancer stem cell impact on clinical oncology. World J Stem Cells. 2019; 10(12):183-195. PMC: 6306557. DOI: 10.4252/wjsc.v10.i12.183. View

15.

Aouacheria A, Baghdiguian S, Lamb H, Huska J, Pineda F, Hardwick J . Connecting mitochondrial dynamics and life-or-death events via Bcl-2 family proteins. Neurochem Int. 2017; 109:141-161. PMC: 5641228. DOI: 10.1016/j.neuint.2017.04.009. View

16.

Inoue H, Kato T, Olugbile S, Tamura K, Chung S, Miyamoto T . Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 2016; 7(12):13621-33. PMC: 4924666. DOI: 10.18632/oncotarget.7297. View

17.

Manic G, Sistigu A, Corradi F, Musella M, De Maria R, Vitale I . Replication stress response in cancer stem cells as a target for chemotherapy. Semin Cancer Biol. 2018; 53:31-41. DOI: 10.1016/j.semcancer.2018.08.003. View

18.

Xia P, Xu X . PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015; 5(5):1602-9. PMC: 4497429. View

19.

Safa A, Pollok K . Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers (Basel). 2012; 3(2):1639-71. PMC: 3281420. DOI: 10.3390/cancers3021639. View

20.

Snyder V, Reed-Newman T, Arnold L, Thomas S, Anant S . Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol. 2018; 8:203. PMC: 5996058. DOI: 10.3389/fonc.2018.00203. View